Galectin Therapeutics (NASDAQ:GALT) Stock Rating Upgraded by Wall Street Zen

Galectin Therapeutics (NASDAQ:GALT - Get Free Report) was upgraded by stock analysts at Wall Street Zen from a "sell" rating to a "hold" rating in a research note issued to investors on Saturday.

Separately, HC Wainwright assumed coverage on shares of Galectin Therapeutics in a research report on Tuesday. They set a "buy" rating and a $6.00 price target for the company.

Galectin Therapeutics Price Performance

Shares of GALT opened at $2.42 on Friday. Galectin Therapeutics has a 1-year low of $0.73 and a 1-year high of $3.90. The stock has a market cap of $153.16 million, a PE ratio of -3.36 and a beta of 0.54. The firm has a 50-day simple moving average of $1.45 and a two-hundred day simple moving average of $1.44.

Galectin Therapeutics (NASDAQ:GALT - Get Free Report) last announced its quarterly earnings results on Thursday, May 15th. The company reported ($0.15) earnings per share for the quarter, beating analysts' consensus estimates of ($0.20) by $0.05. As a group, sell-side analysts expect that Galectin Therapeutics will post -0.73 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in GALT. Bank of New York Mellon Corp grew its holdings in shares of Galectin Therapeutics by 19.0% in the fourth quarter. Bank of New York Mellon Corp now owns 50,826 shares of the company's stock valued at $66,000 after purchasing an additional 8,105 shares in the last quarter. PNC Financial Services Group Inc. acquired a new position in shares of Galectin Therapeutics in the fourth quarter valued at approximately $26,000. Inspire Advisors LLC grew its holdings in shares of Galectin Therapeutics by 86.3% in the fourth quarter. Inspire Advisors LLC now owns 21,095 shares of the company's stock valued at $27,000 after purchasing an additional 9,772 shares in the last quarter. HighTower Advisors LLC acquired a new position in shares of Galectin Therapeutics in the fourth quarter valued at approximately $29,000. Finally, LPL Financial LLC grew its holdings in shares of Galectin Therapeutics by 69.6% in the fourth quarter. LPL Financial LLC now owns 138,928 shares of the company's stock valued at $179,000 after purchasing an additional 57,020 shares in the last quarter. Institutional investors and hedge funds own 11.68% of the company's stock.

Galectin Therapeutics Company Profile

Galectin Therapeutics Inc, a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases. Its lead product candidate is belapectin (GR-MD-02) galectin-3 inhibitor, that is in Phase 2b/3 clinical trial, to prevent esophageal varices in patient with non-alcoholic steatohepatitis (NASH) cirrhosis; and Phase 2 clinical trial for the treatment of liver fibrosis, as well as severe skin disease, and melanoma and head and neck squamous cell carcinoma.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.